Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials. Recently, the crystal structures of PD-L1 in complex wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun Tae, Lee, Ju Yeon, Lim, Heejin, Lee, Sang Hyung, Moon, Yu Jeong, Pyo, Hyo Jeong, Ryu, Seong Eon, Shin, Woori, Heo, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514103/
https://www.ncbi.nlm.nih.gov/pubmed/28717238
http://dx.doi.org/10.1038/s41598-017-06002-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514103/
https://www.ncbi.nlm.nih.gov/pubmed/28717238
http://dx.doi.org/10.1038/s41598-017-06002-8

Ejemplares similares